朱开润, 解成兰, 杨晓倩, 金文杰. 利多卡因治疗癌性疼痛研究进展[J]. 实用临床医药杂志, 2023, 27(22): 131-137. DOI: 10.7619/jcmp.20232163
引用本文: 朱开润, 解成兰, 杨晓倩, 金文杰. 利多卡因治疗癌性疼痛研究进展[J]. 实用临床医药杂志, 2023, 27(22): 131-137. DOI: 10.7619/jcmp.20232163
ZHU Kairun, XIE Chenglan, YANG Xiaoqian, JIN Wenjie. Research progress of lidocaine in the treatment of cancer pain[J]. Journal of Clinical Medicine in Practice, 2023, 27(22): 131-137. DOI: 10.7619/jcmp.20232163
Citation: ZHU Kairun, XIE Chenglan, YANG Xiaoqian, JIN Wenjie. Research progress of lidocaine in the treatment of cancer pain[J]. Journal of Clinical Medicine in Practice, 2023, 27(22): 131-137. DOI: 10.7619/jcmp.20232163

利多卡因治疗癌性疼痛研究进展

Research progress of lidocaine in the treatment of cancer pain

  • 摘要: 疼痛贯穿癌症患者整个疾病过程,其发生机制复杂,涉及肿瘤微环境、癌性骨痛、癌性内脏痛、癌性神经病理性疼痛和手术及化放疗等相关因素。研究表明利多卡因可以缓解阿片类药物难治性癌痛,其治疗各种类型癌痛的作用机制可能也不同,涉及对酸感离子通道(ASICS)、瞬时受体电位通道(TRP)、电压门控钠通道(VGSCs)、神经生长因子(NGF)、谷氨酸及其受体、炎症细胞及细胞因子、小胶质细胞、星形胶质细胞、高迁移率蛋白B1(HMGB1)的调节。本文就癌痛的发生机制和利多卡因治疗不同类型癌痛的作用机制及其临床应用予以综述。

     

    Abstract: Pain permeates the entire process of cancer, and its mechanism is complex, involving tumor microenvironment, cancer-related bone pain, cancer-related visceral pain, cancer-related neuropathic pain, and surgery and radiotherapy-related factors. Studies have indicated that lidocaine can alleviate intractable cancer pain for opioids, and its mechanism of action in treating various types of cancer pain may also be different, involving the regulation of acid-sensing ion channels (ASICS), transient receptor potential channels (TRP), voltage-gated sodium channels (VGSCs), nerve growth factor (NGF), glutamate and its receptors, inflammatory cells and cytokines, microglia, astrocytes, and high mobility group box 1 protein (HMGB1). This paper reviewed the mechanisms of cancer pain, the mechanisms of lidocaine in treating different types of cancer pain as well as its clinical applications.

     

/

返回文章
返回